Up­stream Bio match­es first fund­ing round with an­oth­er $200M to get asth­ma drug to PhI­II

Up­stream Bio has raised an­oth­er $200 mil­lion to go through Phase II stud­ies and pre­pare for late-stage tri­als of an ex-Astel­las mon­o­clon­al an­ti­body in an­tic­i­pa­tion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER